Showing 1 - 20 results of 14,186 for search '(( five ((non decrease) OR (a decrease)) ) OR ( a ((greatest decrease) OR (largest decrease)) ))', query time: 0.57s Refine Results
  1. 1
  2. 2

    Differentially expressed genes (DEGs)<sup>a</sup> showing the greatest fold changes from each potato tissue: 10 with greatest increase in expression and 10 with greatest decrease in expression. by Margaret A. Carpenter (6104180)

    Published 2025
    “…<p>Differentially expressed genes (DEGs)<sup>a</sup> showing the greatest fold changes from each potato tissue: 10 with greatest increase in expression and 10 with greatest decrease in expression.…”
  3. 3
  4. 4
  5. 5

    Inhibition of NEAT1 decreased the miR-204-5p expression and increased Six1 expression. by Lei Li (29537)

    Published 2024
    “…<p>(A) NEAT1 expression following siRNA transfection in BEAS-2B cells; (B-D) The expression of NEAT1, miR-204-5p, and Six1 after decreasing NEAT1 expression. * p <0.05, *** p < 0.001, and **** p <0.0001.…”
  6. 6

    Validation of genetic markers for risk of OA or knee OA for decrease in minJSW. by Mieke L. M. Bentvelzen (21594442)

    Published 2025
    “…<p><b>(A)</b> Manhattan plot of minJSW decrease at 24 months. …”
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16

    Does a correlation exist between delayed vaccination and a decreased vaccine confidence? by Virginia Reverte (9046494)

    Published 2024
    “…Online questionnaire was sent to their parents, followed by a telephone questionnaire for non-responders. Regarding MMR first dose, a significant association was found between delay and birth order and intellectual/motor delay of children. …”
  17. 17

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  18. 18
  19. 19
  20. 20

    EQ-5D-5L index by different chronic conditions. by Hai Minh Vu (17509346)

    Published 2025
    “…Participants with rheumatoid arthritis (β =  − 0.10; 95% CI =  − 0.13, − 0.07) and postural hypotension (β =  − 0.08; 95% CI =  − 0.14, − 0.02) experienced the greatest decrease in EQ-5D index, followed by those with urinary diseases (β =  − 0.05; 95% CI =  − 0.09, − 0.02) and stroke (β =  − 0.05; 95% CI =  − 0.09, − 0.01). …”